Improved Electrophile Design for Exquisite Covalent Molecule Selectivity

José L. Montaña, Brian J. Wang, Regan F. Volk, Virginia G. Garda, Balyn W. Zaro*

Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305.

KEYWORDS: covalent inhibitor, chemical proteomics, drug development, drug selectivity

ABSTRACT: Covalent inhibitors continue to show therapeutic promise. However, off-target reactivity challenges the field. Extensive efforts have been exerted to solve this issue by varying the reactivity attributes of electrophilic warheads, with features such as reversibility or metabolic vulnerability. Here we report the development of a new approach to increase the selectivity of covalent probes and small molecule inhibitors that is independent of warhead reactivity features and can be used in concert with already-existing methods. Using the Bruton's Tyrosine Kinase (BTK) inhibitor Ibrutinib scaffold for our proof-of-concept, we reasoned that increasing the steric bulk of fumarate-based electrophiles on Ibrutinib should improve selectivity via the steric exclusion of off-targets but ideally retain rates of cysteine reactivity comparable to that of an acrylamide. Using chemical proteomic techniques, we demonstrate that elaboration of the electrophile to a *tert*-Butyl (*t*-Bu) fumarate ester significantly decreases time-dependent off-target reactivity and abolishes time-independent off-target reactivity but retains BTK target engagement. While an alkyne-bearing probe analog of Ibrutinib has 247 protein targets, our *t*-Bu fumarate Ibrutinib probe analog has only 7 protein targets. Of these 7 targets, BTK is the only time-independent target. This 2-order-of-magnitude increase in selectivity is also conferred to the *t*-Bu inhibitor itself. By shotgun proteomics, we investigated the consequences of treatment with Ibrutinib and our *t*-Bu analog and discovered that only 8 proteins are downregulated in response to treatment with the *t*-Bu analog compared to 107 with Ibrutinib. Of these 8 proteins, 7 are also downregulated by Ibrutinib and a majority of these targets are associated with BTK biology. Taken together, these findings reveal a previously-unappreciated opportunity to increase cysteine-reactive covalent inhibitor selectivity through electrophilic structure optimization.

INTRODUCTION

Irreversible covalent molecules have long been explored as therapeutics in human disease. Their irreversible mechanism of action (MoA) is believed to i) minimize the risk of treatment-acquired mutations which can lead to drug-resistance and ii) lower both the dose and frequency of drug administration.¹ However, the very same characteristic that has endowed these molecules with these attractive features has also elicited much skepticism in their potential to be safe and viable long-term therapeutics. Mainly, much like the target engagement of their intended target, any off-targets of irreversible inhibitors may also be engaged irreversibly. Nonetheless, there are currently over 40 covalent inhibitors approved by the FDA for the treatment of several clinical indications, including cancer.² The success of these drugs in the clinic likely stems from careful structure-activity relationship (SAR) studies that yield highly selective inhibitors and, in some instances, clever exploitation of unique nucleophilic residues on proteins (i.e. cysteines on kinases) which may further improve the molecule's selectivity across the proteome. Despite the clinical success, recent advances in chemical proteomic methods have revealed the off-target promiscuity of these covalent kinase inhibitors extends to both kinase and non-kinase proteins. Critically, this off-target reactivity may be associated with target-independent cytotoxicity. Much of this off-target reactivity is time-dependent, meaning that while initially these inhibitors are quite selective for

their intended target, they begin to engage off-targets over time.³

Many creative approaches have been applied to solve this problem. The design of covalent reversible inhibitors has emerged as a viable strategy, demonstrating improved selectivity by engaging on-targets more durably compared to off-targets.⁴⁻⁶ The use of covalent reactive groups ('warheads') with tunable reactivity has also been successful in developing more selective covalent inhibitors.^{7,8} Additionally, we have previously shown that the use of metabolically labile warheads can result in inhibitors with kinetic-selectivity and decreased time-dependent off-target engagement events.⁹ In this approach, the acrylamide (Michael acceptor) of the Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib, was replaced with a methyl fumarate. This yielded a highly reactive warhead that engages BTK at a much faster rate than its inactivation by human carboxylesterase 1 (hCES1), but reduces time-dependent off-target engagement. However, in the absence of hCES1, the methyl fumarate analogue probe of Ibrutinib has increased free-cysteine reactivity and significantly higher-background labelling compared to the parent Ibrutinib probe.

Crystal structures of Ibrutinib covalently bound to Cys481 of BTK indicate the presence of available space for the elaboration of electrophiles appended to the Ibrutinib scaffold.¹⁰ This prompted us to ask if the presence of this cavity would allow inhibitors with bulkier electrophiles to retain BTK engagement,

while reducing off-targets via steric exclusion. Although fumarate-based warheads can be easily derivatized to yield electrophiles with varying levels of steric bulk, the ester substituent of fumarates can drastically alter the overall reactivity of the $\alpha\beta$ -unsaturated carbonyl. Therefore, we wondered if we could develop Ibrutinib analogues containing fumarate-based warheads that are i) relatively sterically bulky and ii) as cysteine reactive as the acrylamide on Ibrutinib.

RESULTS

We developed a small library of fumarate analogues of Ibrutinib (**1**), each with increasing bulk and varying levels of electron donating properties (Figure 1a). To assess the overall reactivity of inhibitors **1-4**, we carried out a cysteine reactivity assay. The *tert*-Butyl fumarate (*t*-Bu) analogue (**3**) possesses a reactivity comparable to that of the acrylamide parent compound (**1**) ($28.69 \pm 2.18 \text{ L mol}^{-1} \text{ min}^{-1}$ and $17.81 \pm 1.88 \text{ L mol}^{-1} \text{ min}^{-1}$, respectively), while **2** and **4** has significantly greater reactivity towards free reduced cysteine (Figure 1b). Intrigued by these results, we then asked if **3** was still capable of engaging BTK despite its increased bulk at the electrophilic moiety. We further modified Ibrutinib (**1**) and its fumarate ester analogues (**2-4**) with alkyne handles to yield probes **5-8** (Figure 1a).

Figure 1. Design and initial cysteine reactivity assessment of fumarate-based Ibrutinib analogues. (a) Structures of inhibitors and probes used in this study. (b) Comparison of the reactivity of **1-4** *in vitro* in a cysteine binding assay using Ellman's reagent. Whereas the reactivity of **1** and **3** were comparable, the free reduced cysteine levels were more rapidly decreased in the presence of **2** and **4**. The second-order rate constants were calculated and are presented in the table to the right.

To qualitatively compare global reactivity profiles and assess BTK target engagement of **5-8**, we took advantage of established gel-based chemical probe labeling techniques.^{13,14} Whole Mino cells were subjected to increasing concentrations of probe (**5-8**; 1 nM – 1 μM , 16 h) prior to lysis and conjugation of TAMRA-azide via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) followed by SDS-PAGE and in-gel fluorescence scanning. Remarkably, while probes **5**, **6**, and **8** began showing significant off-target activity at 1 μM , probe **7** remained highly selective for BTK (Figure 2a). Since it is known that many covalent drugs, including Ibrutinib, have time-dependent off-target activity^{2,15}, we next tested the time-dependent labelling of proteins by probes **5-8** (1 μM , 1 – 24 h). After 1 hour, each

probe, with the exception of **8**, appeared to engage BTK selectively. However, by 8 hours, all probes with the exception of **7**, began to qualitatively display time-dependent promiscuity (Figure 2b).

Figure 2. In-gel characterization of global protein labelling by fumarate-based Ibrutinib probes. (a) In-gel fluorescence scanning data for concentration-dependent (1 nM - 1 μM ; 16 h) and (b) time-dependent (1 h - 24 h; 1 μM) labelling of proteins in whole Mino cells by probes **5-8**. In both cases, TAMRA-azide was conjugated onto labelled protein via CuAAC prior to SDS-PAGE

With what appeared to be a highly selective probe for BTK in hand, we went on to compare protein targets of the original Ibrutinib probe (**5**, IbAlk) and the new *t*-Bu probe (**7**, Ib*t*BuAlk) using comparative MS-based chemical proteomics techniques. To generate a list of true probe targets for **5** and **7**, isotopically-labelled 'heavy' or 'light' cultures of Mino cells were treated with probe (**5** or **7**; 1 μM , 24 h) or no probe (DMSO), respectively, prior to lysis and 1:1 mixing of heavy/light (probe/no probe) lysate pairs. Proteins covalently engaged by probe were enriched via biotin-azide CuAAC conjugation followed by streptavidin enrichment, tryptic digest and LC-MS analysis (Figure S1, Tables S1 and S2). In this approach, proteins preferentially enriched by a probe are identified by having a characteristic probe versus (vs) DMSO vehicle SILAC enrichment ratio of ≥ 2 . While we were able to identify only 7 true targets of probe **7**, we identified 247 targets for probe **5** (Tables S3 and S4). Notably, all 7 targets of probe **7**, including BTK, are also shared with probe **5** (Figure 3a).

Previous reports by ourselves and others have highlighted the time-dependent and -independent protein targets of covalent inhibitors and probes. Therefore, we were curious to see if probe 7 would also have a similar distinction between targets. We performed comparative MS-based time course experiments, where isotopically labelled Mino cells were dosed with probe (5 or 7;

1 μ M) for either 1 hour or 24 hours (Figure S1). An enrichment ratio was generated comparing probe enrichment following 24 h of probe treatment compared to 1h of probe treatment (24 h/1 h) (Tables S5 and S6). We binned time-dependence for true targets of each probe into 3 categories: i) time-independent (Enrichment Ratio 24 h vs 1 h < 2), ii) moderately time-dependent

Figure 3. SILAC-based quantitative proteomic analysis of IbAlk and IbtBuAlk protein targets. (a) Probe vs no probe SILAC analysis identified a total of 247 targets of IbAlk (5) and 7 targets for IbtBuAlk (7). All 7 protein targets of IbtBuAlk were also found to be targets of IbAlk. (b) Volcano plot of proteins enriched by IbAlk and (c) IbtBuAlk from SILAC-ABPP probe vs no probe experiments. Size of bubbles indicates whether a protein target is either i) time-independent, ii) moderately time-dependent, or iii) highly time-dependent as determined from separate SILAC-ABPP 1 h vs 24 h experiments. (d) Bar graphs showing the total protein targets for each probe and their time-dependence. Of the 7 protein targets of IbtBuAlk, the only time-independent target was BTK. (e) Waterfall plot of proteins preferentially enriched by either IbtBuAlk or IbAlk in SILAC-ABPP probe vs probe experiments.

(Enrichment Ratio 24h vs 1h $2 \leq X < 4$) and iii) highly time-dependent (Enrichment Ratio 24h vs 1h ≥ 4) (Figures 3b and 3c, Figures S3a and S3b). Importantly, enrichment of BTK between 1 hour and 24 hours was unchanged (enrichment ratio ~ 1)

for both 5 and 7, indicating saturated target engagement of BTK by both probes within 1 h of treatment. However, while 5 had over 100 time-dependent targets, 7 had only 6 (Figure 3d,

Figure S3c). Strikingly, BTK was the only time-independent target of **7**.

To directly compare the reactivity of **5** and **7** over 24 hours, probe vs probe comparative SILAC studies were performed (Figure S1). Isotopically heavy or light Mino cells were treated with indicated probe (**5** or **7**; 1 μ M). While BTK enrichment

was comparable for both probes following 24 hour treatment, global reactivity of **5** was markedly higher with 53 proteins preferentially enriched by **5** compared to 4 by **7** (Figure 3e, Figure S4, Table S7). Known off-targets of both probes such as PFKAL, CYB5B, and HMOX2 were each preferentially enriched by **5** (Figure 3e).

Figure 4. Characterization of proteins competed away by pre-treatment with Ibrutinib and IbtBu inhibitors. (a) Gel-based competitive ABPP showing differences in protein enrichment profile in Mino cells pre-treated with either DMSO, Ibrutinib (**1**) or IbtBu (**3**) for 1 hour at 10 μ M and chased with either IbAlk (**5**) (lanes 1-3) or IbtBuAlk (**7**) (lanes 4-6). The dark band at about 75 kD is BTK. (b) Plot showing proteins competed away by i) both Ib and IbtBu, ii) only Ib and iii) only IbtBu in competition probe labelling SILAC experiments. Ratios from both Ib (red circles) and IbtBu (blue circles) competition are plotted for each protein. Proteins which appeared to be competed were also required to have a significance value of ≥ 20 ($p \leq 0.01$). (c) Bar graph comparing the total number of proteins competed away by competition with either Ibrutinib or IbtBu as determined by probe labelling SILAC experiments.

Having confirmed that **7** was more selective for BTK than **5** in a time-dependent and -independent manner, we next asked if this increase in selectivity was conferred by the inhibitor. For gel-based competitive probe experiments, Mino cells were pre-treated with either DMSO or inhibitor (**1** or **3**; 10 μ M, 1 h). Following pre-treatment, the indicated probe was added (**5** or **7**; 1 μ M, 16 h) prior to downstream processing for in-gel fluorescence scanning. While both inhibitors competed away BTK probe labeling, we noticed that some bands labeled by **5** were competed by **1** and not **3**, examples of which are denoted with red asterisks (Figure 4a).

We complemented these competitive gel-based experiments with MS-based studies. We binned probe **5** targets as i) non-competed (enrichment ratio > 0.5), ii) moderately competed (enrichment ratio $0.25 < X \leq 0.5$), or iii) highly competed (enrichment ratio ≤ 0.25) (Figure 4b, Tables S8 and S9). BTK target engagement by **3** was comparable to that of **1** in competing away labeling by **5**. In total, 10 protein targets were competed by pre-treatment with both **1** and **3** (Figure 4b). There was also a large subset of proteins engaged by **1** and not by **3**, while only 3 proteins were uniquely competed by **3**. In total, **1** competed

44 targets compared to 13 by **3** (Figure 4c, Figure S5a and S5b). Taken together, these results indicate that the *t*-Bu fumarate ester analogue is exceptionally selective for BTK.

Given the differences in reactivity between our *t*-Bu fumarate-bearing compound and the parent acrylamide compound, we wondered if the proteomic consequences of inhibitor treatment would differ. To that end, Mino cells were treated with **1**, **3** or DMSO control (1 μ M, 48 h) and processed for shotgun whole protein MS analysis. Using label-free quantification methods we identified approximately 3500 proteins across each dataset run in biological and technical duplicate, a subset of which were down-regulated in response to inhibitor treatment compared to DMSO (≥ 2 -fold change, Figure 5a and 5b). Treatment with **1** resulted in the downregulation of 107 proteins compared to only 8 proteins when cells were treated with **3** (Figure 5a and 5b, Tables S10 and S11). Of the 8 proteins downregulated upon treatment with **3**, 7 were also downregulated by **1** (Figure 5c). Of these 7 overlapping proteins, 5 are implicated in B-cell receptor signaling (Figure 5c).¹⁶⁻²³

Finally, we asked if these differences in promiscuity would alter cytotoxicity profiles. Mino cells were treated with **1** or **3**

at increasing concentrations for 48 h. Cell viability assays revealed differing toxicity profiles between both inhibitors (Figure 6). Whereas the EC₅₀ value for **1** was $11.12 \pm 0.84 \mu\text{M}$, **3** had an EC₅₀ of $6.25 \pm 0.65 \mu\text{M}$, indicating an increase in toxicity. From our comparative proteomics experiments we know both compounds engage BTK similarly, so we postulate this

difference in viability profile is due to differences in off-target reactivity.

Figure 5. Assessment of global proteome changes in inhibitor treated Mino cells. (a) Volcano plot showing the changes in protein expression levels as a result of treatment with inhibitor 1 (Ib; 1 μM , 48 h) or (b) inhibitor 3 (IbtBu; 1 μM , 48 h). Values are all relative to DMSO control treated cells. (c) Breakdown of the down-regulated proteins in both Ib and IbtBu treated Mino cells. While Ib treatment resulted in the down-regulation of 107 proteins, treatment with IbtBu resulted in the down-regulation of only 8 proteins, 7 of which were shared between both conditions. Listed shared proteins are shown to the right. Bolded proteins represent proteins previously implicated in BCR signaling.

DISCUSSION

Here, we describe a new and overlooked strategy in the development of highly-selective irreversible covalent inhibitors. As a proof-of-concept, we developed fumarate-based analogues of Ibrutinib, each one possessing varying levels of steric bulk and electron-donating properties. We found that while methyl- and phenyl-fumarate ester analogues of Ibrutinib were highly reactive towards free reduced cysteine, a *t*-Bu fumarate ester possessed a reactivity comparable to that of the acrylamide-equipped parent compound. We further tested the selectivity of our analogues relative to Ibrutinib by furnishing each one with an alkyne handle and carrying out established gel- and mass spectrometry (MS)-based probe experiments. Despite having similar reactivities, the *t*-Bu fumarate ester probe was exquisitely selective for BTK in both concentration- and time-dependent labelling experiments relative to the Ibrutinib probe. This was demonstrated both qualitatively by in-gel fluorescence scanning experiments and quantitatively in SILAC-based MS experiments. Competition experiments further validated that the selectivity of the *t*-Bu fumarate ester probe analogue of Ibrutinib was also conferred by its inhibitor counterpart. Shotgun proteomics of cells treated with either Ibrutinib or the *t*-Bu fumarate ester inhibitor revealed striking differences in their relative protein abundance profiles. While treatment with Ibrutinib led to the downregulation of 107 protein relative to vehicle treated cells, treatment with the *t*-Bu fumarate ester inhibitor resulted in the downregulation of just 8 proteins. Of these 8 proteins, 7 were also downregulated by Ibrutinib treatment, and 5 out of the 7 shared downregulated proteins have been previously implicated in B-cell receptor signaling.

Our results offer yet another strategy which can be implemented in the development of more selective covalent inhibitors. Importantly, while previous methods have obtained selectivity through modifications that alter the reactivity of the electrophile, our approach achieves selectivity in a manner in which

cysteine reactivity is comparable to the original inhibitor. We demonstrate that warhead structure elaboration and optimization can augment the overall inherent selectivity of covalent inhibitors in a reactivity-independent manner.

Figure 6. Determination of cytotoxicity of Ib and IbtBu inhibitors. Cell viability assay comparing the cytotoxicity profiles of Ib and IbtBu in Mino cells. Points represent the mean of three replicates and the standard error of the mean (SEM) are plotted.

Traditionally, covalent drug discovery campaigns mainly focus on scaffold optimization. This ultimately results in unique molecules with exceptional initial selectivity towards their intended target. However, much of the off-target engagement that occurs with irreversible covalent inhibitors is time-dependent, and this undesirable reactivity may ultimately go unnoticed within the timeframe of classical screening techniques (minutes to a few hours). In addition, in the case of covalent kinase inhibitors, many inhibitors are screened exclusively for off-target kinase reactivity.²⁴ However, our studies and others also demonstrate that many off-targets of these molecules are non-kinases.^{2,8,25} Creative efforts to improve the selectivity of covalent inhibitors have been reported, and in special cases where the nucleophilicity of an amino acid residue is increased due to its microenvironment, selectivity can be achieved by simply

using warheads with reduced reactivity.⁸ The use of warheads that form reversible covalent bonds to inhibit their targets has also been successful in developing potent and selective covalent inhibitors with a reversible MoA.²⁶ Incorporating metabolic vulnerabilities to the warhead has led to kinetically selective covalent inhibitors which rapidly engage their intended targets but become deactivated overtime by esterases thereby minimizing any time-dependent off-target reactivity.

Although the abovementioned methods have expanded the repertoire of electrophiles amenable to covalent inhibitors, they each have unique use-cases, thus limiting their overall utility. Therefore, more generalizable methods to increase the selectivity of covalent probes and small molecule inhibitors are needed. We now report that elaboration of the electrophilic moiety can directly impart greater overall selectivity simply due to its own structure without a change in its reactivity or dependence on metabolic inactivation. We believe that electrophile structure optimization may be used in conjunction with scaffold optimization to obtain highly selective covalent inhibitors.

While our work represents a novel approach to improve covalent inhibitor selectivity, we recognize that it is limited to protein targets that can accept a larger electrophile, such as BTK.⁹ Ongoing work in our laboratory involves identifying other attractive protein targets, in particular kinases, which may also be amenable to this approach. Despite this limitation, it is worth noting that BTK has been, and continues to be, an attractive target for covalent inhibitors due to its role in the development of B-cell malignancies. Notably, as of 2020, there were 5 covalent inhibitors of BTK in clinical trials, 3 of which utilize an acrylamide warhead to carry out their inhibition.²⁵ Our findings presented here highlight an unprecedented optimization opportunity currently available to covalent inhibitors of BTK.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Methods and materials (PDF)

Protein characterization (XLSX)

AUTHOR INFORMATION

Corresponding Author

Balyn W. Zaro – Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305, United States; orcid

Email: Balyn.Zaro@ucsf.edu

Authors

José L. Montaña – Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305, United States; orcid

Brian J. Wang – Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305, United States; orcid

Regan F. Volk – Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305, United States; orcid

Virginia G. Garda – Department of Pharmaceutical Chemistry and Cardiovascular Research Institute University, University of California, San Francisco, CA 94305, United States; orcid

Author Contributions

BWZ and JLM prepared and wrote the manuscript. Experiments were conducted by JLM, BJW, RFV and VGG. All authors have given approval of the final version of the manuscript.

Funding Sources

This work was supported through the Beckman Young Investigator Program from the Arnold O. and Mabel Beckman Foundation (to BWZ); a National Science Foundation Graduate Research Fellowship under grant no. DGE-2034836 (to JLM); and the University of California, San Francisco.

ACKNOWLEDGMENT

We thank M.R. Pratt for careful reading of the manuscript and S. Vigneron and L. Chen for useful discussions. JLM would also like to thank Jón Þór Birgisson *et al.* and for essential assistance.

ABBREVIATIONS

BTK, Bruton's Tyrosine Kinase; Ib, Ibrutinib; IbtBu, Ibrutinib-*t*-butyl; IbAlk, Ibrutinib-Alkyne; IbtBuAlk, Ibrutinib-*t*-butyl-alkyne.

REFERENCES

- (1) Ferguson, F. M.; Gray, N. S. Kinase Inhibitors: The Road Ahead. *Nature Reviews Drug Discovery* 2018, 17 (5), 353–377. <https://doi.org/10.1038/nrd.2018.21>.
- (2) Bauer, R. A. Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies. *Drug Discovery Today* 2015, 20 (9), 1061–1073. <https://doi.org/https://doi.org/10.1016/j.drudis.2015.05.005>.
- (3) Lanning, B. R.; Whitby, L. R.; Dix, M. M.; Douhan, J.; Gilbert, A. M.; Hett, E. C.; Johnson, T. O.; Joslyn, C.; Kath, J. C.; Niessen, S.; Roberts, L. R.; Schnute, M. E.; Wang, C.; Hulce, J. J.; Wei, B.; Whiteley, L. O.; Hayward, M. M.; Cravatt, B. F. A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors. *Nature Chemical Biology* 2014, 10 (9), 760–767. <https://doi.org/10.1038/nchembio.1582>.
- (4) Senkane, K.; Vinogradova, E. v.; Suci, R. M.; Crowley, V. M.; Zaro, B. W.; Bradshaw, J. M.; Brameld, K. A.; Cravatt, B. F. The Proteome-Wide Potential for Reversible Covalency at Cysteine. *Angewandte Chemie International Edition* 2019, 58 (33), 11385–11389. <https://doi.org/https://doi.org/10.1002/anie.201905829>.
- (5) Miller, R. M.; Paavilainen, V. O.; Krishnan, S.; Serafimova, I. M.; Taunton, J. Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors. *Journal of the American Chemical Society* 2013, 135 (14), 5298–5301. <https://doi.org/10.1021/ja401221b>.
- (6) Serafimova, I. M.; Pufall, M. A.; Krishnan, S.; Duda, K.; Cohen, M. S.; Maglathlin, R. L.; McFarland, J. M.; Miller, R. M.; Frödin, M.; Taunton, J. Reversible Targeting of Noncatalytic Cysteines with Chemically Tuned Electrophiles. *Nature Chemical Biology* 2012, 8 (5), 471–476. <https://doi.org/10.1038/nchembio.925>.
- (7) Shindo, N.; Fuchida, H.; Sato, M.; Watari, K.; Shibata, T.; Kuwata, K.; Miura, C.; Okamoto, K.; Hatsuyama, Y.; Tokunaga, K.; Sakamoto, S.; Morimoto, S.; Abe, Y.; Shiroishi, M.; Caaveiro, J. M. M.; Ueda, T.; Tamura, T.; Matsunaga, N.; Nakao, T.; Koyanagi, S.; Ohdo, S.; Yamaguchi, Y.; Hamachi, I.; Ono, M.; Ojida, A. Selective and Reversible Modification of Kinase Cysteines with Chlorofluoroacetamides. *Nature Chemical Biology* 2019, 15 (3), 250–258. <https://doi.org/10.1038/s41589-018-0204-3>.
- (8) Barf, T.; Covey, T.; Izumi, R.; van de Kar, B.; Gulrajani, M.; van Lith, B.; van Hoek, M.; de Zwart, E.; Mittag, D.; Demont, D.; Verkaik, S.; Krantz, F.; Pearson, P. G.; Ulrich, R.; Kaptein, A. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.

- Journal of Pharmacology and Experimental Therapeutics 2017, 363 (2), 240 LP – 252. <https://doi.org/10.1124/jpet.117.242909>.
- (9) Zaro, B. W.; Whitby, L. R.; Lum, K. M.; Cravatt, B. F. Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors. *Journal of the American Chemical Society* 2016, 138 (49), 15841–15844. <https://doi.org/10.1021/jacs.6b10589>.
- (10) Bender, A. T.; Gardberg, A.; Pereira, A.; Johnson, T.; Wu, Y.; Grenningloh, R.; Head, J.; Morandi, F.; Haselmayer, P.; Liu-Bujalski, L. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but Not B-Cell Receptor Signaling. *Molecular Pharmacology* 2017, 91 (3), 208 LP – 219. <https://doi.org/10.1124/mol.116.107037>.
- (11) Speers, A. E.; Adam, G. C.; Cravatt, B. F. Activity-Based Protein Profiling in Vivo Using a Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition. *Journal of the American Chemical Society* 2003, 125 (16), 4686–4687. <https://doi.org/10.1021/ja034490h>.
- (12) Parker, C. G.; Pratt, M. R. Click Chemistry in Proteomic Investigations. *Cell* 2020, 180 (4), 605–632. <https://doi.org/https://doi.org/10.1016/j.cell.2020.01.025>.
- (13) Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. *Chemistry & Biology* 2013, 20 (2), 146–159. <https://doi.org/https://doi.org/10.1016/j.chembiol.2012.12.006>.
- (14) Hondares, E.; Brown, M. A.; Musset, B.; Morgan, D.; Cherny, V. v.; Taubert, C.; Bhamrah, M. K.; Coe, D.; Marelli-Berg, F.; Gribben, J. G.; Dyer, M. J. S.; DeCoursey, T. E.; Capasso, M. Enhanced Activation of an Amino-Terminally Truncated Isoform of the Voltage-Gated Proton Channel HVCN1 Enriched in Malignant B Cells. *Proceedings of the National Academy of Sciences* 2014, 111 (50), 18078 LP – 18083. <https://doi.org/10.1073/pnas.1411390111>.
- (15) Capasso, M.; Bhamrah, M. K.; Henley, T.; Boyd, R. S.; Langlais, C.; Cain, K.; Dinsdale, D.; Pulford, K.; Khan, M.; Musset, B.; Cherny, V. v.; Morgan, D.; Gascoyne, R. D.; Vigorito, E.; DeCoursey, T. E.; MacLennan, I. C. M.; Dyer, M. J. S. HVCN1 Modulates BCR Signal Strength via Regulation of BCR-Dependent Generation of Reactive Oxygen Species. *Nature Immunology* 2010, 11 (3), 265–272. <https://doi.org/10.1038/ni.1843>.
- (16) Nagel, D.; Vincendeau, M.; Eitelhuber, A. C.; Krappmann, D. Mechanisms and Consequences of Constitutive NF-KB Activation in B-Cell Lymphoid Malignancies. *Oncogene* 2014, 33 (50), 5655–5665. <https://doi.org/10.1038/onc.2013.565>.
- (17) de Silva, N. S.; Anderson, M. M.; Carette, A.; Silva, K.; Heise, N.; Bhagat, G.; Klein, U. Transcription Factors of the Alternative NF-KB Pathway Are Required for Germinal Center B-Cell Development. *Proceedings of the National Academy of Sciences* 2016, 113 (32), 9063 LP – 9068. <https://doi.org/10.1073/pnas.1602728113>.
- (18) Holland, J.; Owens, T. Signaling through Intercellular Adhesion Molecule 1 (ICAM-1) in a B Cell Lymphoma Line: The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. *Journal of Biological Chemistry* 1997, 272 (14), 9108–9112. <https://doi.org/10.1074/jbc.272.14.9108>.
- (19) Dennig, D.; Lacerda, J.; Yan, Y.; Gasparetto, C.; O'Reilly, R. J. ICAM-1 (CD54) Expression on B Lymphocytes Is Associated with Their Costimulatory Function and Can Be Increased by Coactivation with IL-1 and IL-7. *Cellular Immunology* 1994, 156 (2), 414–423. <https://doi.org/https://doi.org/10.1006/cimm.1994.1186>.
- (20) Sana, I.; Mantione, M. E.; Angelillo, P.; Muzio, M. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies. *Frontiers in Oncology* 2021, p 1044.
- (21) Giampaolo, S.; Wójcik, G.; Klein-Hessling, S.; Serfling, E.; Patra, A. K. B Cell Development Is Critically Dependent on NFATc1 Activity. *Cellular & Molecular Immunology* 2019, 16 (5), 508–520. <https://doi.org/10.1038/s41423-018-0052-9>.
- (22) Uitdehaag, J. C. M.; Verkaar, F.; Alwan, H.; de Man, J.; Buijsman, R. C.; Zaman, G. J. R. A Guide to Picking the Most Selective Kinase Inhibitor Tool Compounds for Pharmacological Validation of Drug Targets. *British journal of pharmacology* 2012, 166 (3), 858–876. <https://doi.org/10.1111/j.1476-5381.2012.01859.x>.
- (23) Susan, K.; Stephanie, H.; Mathias, W.; Harald, P.; Binje, V.; Paul-Albert, K.; Maria, R.; Benjamin, R.; Svenja, P.; Chen, M.; Jana, Z.; Katrin, R.; Huichao, Q.; Dominic, H.; Heiner, K.; Melanie, S.; Giulia, C.; Elena, C.; Re, D. S.; Annette, F.; Zhixiang, W.; Tobias, S.; Lars, R.; Wilhelm, B.; Jan, H.; Anne-Kathrin, G.; Bjoern-Oliver, G.; Paul, Z. D.; Gian, K.; Tonu, V.; Robert, P.; Hannes, H.; Neeme, T.; Karl, K.; Katharina, G.; Florian, B.; Judith, S.; Hans-Christian, E.; Stephan, A.; Axel, W.; A., G. P.; Sabine, S.; Rudolf, F. E.; Juergen, R.; Guillaume, M.; Irmela, J.; Karsten, S.; Bernhard, K. The Target Landscape of Clinical Kinase Drugs. *Science* 2017, 358 (6367), ea4368. <https://doi.org/10.1126/science.aan4368>.
- (24) Bradshaw, J. M.; McFarland, J. M.; Paavilainen, V. O.; Bisconte, A.; Tam, D.; Phan, V. T.; Romanov, S.; Finkle, D.; Shu, J.; Patel, V.; Ton, T.; Li, X.; Loughhead, D. G.; Nunn, P. A.; Karr, D. E.; Geritsen, M. E.; Funk, J. O.; Owens, T. D.; Verner, E.; Brameld, K. A.; Hill, R. J.; Goldstein, D. M.; Taunton, J. Prolonged and Tunable Residence Time Using Reversible Covalent Kinase Inhibitors. *Nature Chemical Biology* 2015, 11 (7), 525–531. <https://doi.org/10.1038/nchembio.1817>.
- (25) Sutanto, F.; Konstantinidou, M.; Dömling, A. Covalent Inhibitors: A Rational Approach to Drug Discovery. *RSC Medicinal Chemistry* 2020, 11 (8), 876–884. <https://doi.org/10.1039/D0MD00154F>.